Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab deruxtecan plus stereotactic radiotherapy in HER2-positive and HER2-low breast cancer brain metastases
ChiCTR2600123184Phase 4Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of trastuzumab deruxtecan in breast cancer and brain metastases (2 cohorts), sponsored by Huashan Hospital. Primary endpoint: Intracranial Objective Response Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2600123184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123184.